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Our Thanks to Herbert Laboratories 
We recognize with appreciation Herbert Laboratories for pledging 
support to the Endowment Fund for The Journal ofInvestigative 
Dermatology, which will be used to support the growth and con-
tinued success of the Journal. This support will certainly strengthen 
and perpetuate the partnership between the pharmaceutical industry 
In its first two decades, Herbert Laboratories has developed a variety 
of medications to help dermatologists better care for their patients. 
In the 1980s, we have greatly expanded our research effort to con-
tinue to meet the needs of the dermatology community. From con-
ducting basic research to sponsoring clinical trials, over this decade 
we have increased our commitment to discovering and developing 
pharmaceuticals for dermatology. 
W e believe that dermatology is at the threshold of an exciting 
new era. Rapid strides are being made in elucidating the physiologi-
cal and immunological mechanisms at work in the skin. The power-
ful techniques of modern molecu lar and cellular biology are provid-
ing researchers with new tools to probe the pathogenesis of skin 
disorders and the mechanisms of action of drugs to combat these 
disorders. In the next decades, this research should provide answers 
to many of the remaining puzzles in cutaneous biology and a wealth 
of new therapies to treat refractory skin diseases. 
DISCOVERY RESEARCH 
The Herbert Laboratories Discovery Research program, our major 
effort in basic dermatology research is focusing on cutaneous in-
flammation and abnormal cell proliferation. These two biologic 
processes are hallmarks of many dermatologic diseases, and to date 
medicine has had only limited success in controlling them. The best 
drugs will undoubtedly emerge from a basic understanding of the 
biochemistry and physiology underlying these processes. 
The search for better anti-inflammatory agents at Herbert Labo-
ratories is centered on phospholipases and selected enzymes of the 
arachidonic acid pathway that are important in the multifaceted 
inflammatory response . We believe new inhibitors of such enzymes 
will eventually occupy an important place in the dermatologist.'s 
armamentarium of anti-inflammatory drugs, and preclinical and 
clinica l studies of such compounds are underway. 
We are also conducting a major research effort to tap the full 
potential of the retinoids in treating disease. Although long recog-
nized as having great promise in modulating abnormal cell prolifer-
ation, the use of retinoids has been limited because of their serious 
side effects. Our scientists are designing and developing retinoid 
compounds with minimal side effects whi le still retaining therapeu-
tic properties. 
With the increasing understanding of the mechanism of action of 
the retinoids, such as the recent cloning of retinoid receptors, and 
our capabilities in sophisticated molecular modeling and rational 
drug design, we are in an excellent position to develop retinoid 
compounds with significant therapeutic advantages. Progress in ret-
inoid research will open new approaches to therapy for many skin 
disorders, including psoriasis, acne, and sun-induced photodamage. 
The proportion of revenue, as a percentage of sales, devoted to 
research by our company is among the highest in the pharmaceuti-
cal industry, reflecting our confidence that a strong program of 
research will bear fruit in coming years in the form of innovative 
and useful new pharmaceuticals. 
and basic and clinical investigators in cutaneous biology. 
We salute Herbert Laboratories for t}uir contribution to the En_ 
dowment Fund and for their continued support of clinical and i,wes_ 
tigatiIJe dermatology. 
D.A.N.) DenIJer) CO 
CLINICAL RESEARCH 
Our Clinical Research program is already bringing therapeutic ad_ 
vances to dermatology . In addition to developing drugs through OUt 
own research, we have been particularly successful in licensing 
promising drugs from abroad. In such cases, our clinical research 
capabilities are still of the utmost importance, since validation of the 
safety and efficacy of compounds in use internationally typically 
requires the completion of U .S. studies that conform with a\l Food 
and Drug Administration standards. The latest products to be intro_ 
duced as a result of this program include a new sunscreen effective 
against long-wave ultraviolet (UV A) and the first of a new class of 
topical antifungals. 
The use of topical agents to prevent and reverse photodamage has 
long been a major interest of Herbert Laboratories. Our company 
was the first in the early 1970s to introduce a topical 5-fluorouracil 
preparation for treatment of actinic keratoses. Recently, we have 
focused on improved topical preparations to protect against UV A, 
which has in recent years been clearly shown to be a source of 
potentially serious photodamage to the skin. UV A-absorbing agents 
promise to be of special benefit to photosensitive patients and pa-
tients concerned with skin damage resulting from chronic sun expo-
sure (photoaging) . 
The development of better drug delivery systems has also been an 
abiding interest of Herbert Laboratories. Research in this area re-
cently made possible the introduction of the first erythromycin gel 
for the treatment of acne. Thus, this method of drug delivery prom-
ises to promote patient compliance, which is essential in achieving 
the desired therapeutic outcome. 
EXTRAMURAL SUPPORT AND 
PROFESSIONAL EDUCATION 
Herbert Laboratories supports basic research in universities and re-
search institutions through fe llowships and grants. Tile Herbert 
Laboratories Research Fellowship and the Eva Ljungwe Research 
Grant are awarded annually by the Dermatology Foundation. Our 
company also provides funding for investigations by clinical re-
searchers and dermatologists in private practice. 
Our dedication to dermatology includes an ongoing program of 
professional education, including the Herbert Laboratories Forum 
series, the distribution of a variety of educational monographs, a 
long-standing educational program for residents, the Advanced 
Seminars in Dermatology, 'and support for more than one hundred 
local, regional, and national organizations involved in skin care. 
Herbert Laboratories is pleased to provide support for the En-
dowment Fund of the jOlwlOf oj Il'lvesligal ilie Dermatology. The Jour-
nal plays an important role in disseminating significant new find-
ings in dermatology research . Basic and clinical dermacologic 
research is the wel lspring of better skin care, and we are delighted to 
support the Journal in its important work of communicating the 
results of such research. F k P K' ll PI) D ran . 1 ey, " 
Vice President, Research and Deve lopment 
Herbert Laboratories 
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